Table of Contents Understanding MASLD and MASH in Clinical Practice Mechanisms Behind GLP1s and Liver Health Clinical Evidence Supporting GLP1 MASLD MASH Treatment Choosing the Right GLP1 Agent Monitoring and Managing Patients on GLP1s Future Directions in Therapy FAQs Understanding MASLD and MASH in Clinical Practice MASLD, previously labeled as nonalcoholic fatty liver disease (NAFLD), is now identified by the presence of liver steatosis in individuals with metabolic dysfunction, excluding significant alcohol consumption
Choose the Best Medication Plan GLP-1s (like semaglutide or tirzepatide injectable or oral), phentermine, or a combination
Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner
This article examines the evidence on concurrent use, potential interactions, monitoring requirements, and safety considerations aligned with UK clinical guidance from NICE, the MHRA, and the BNF
It is important to distinguish between what the MHRA has authorised and what is available on the NHS
If you experience a severe allergic reaction (swelling of face, eyes, and lips, itching, dizziness, and difficulty breathing), gallbladder inflammation, changes in vision, or low blood sugar levels, stop using the medication and get medical help right away